Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 18/20 | 1.00 |
| ▸ | RARB | P10826 | 17/20 | 1.00 |
| ▸ | RARG | P13631 | 14/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 0.67 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4652336 | 0.93 | RARA (0.88) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6239917 | 0.91 | RARB (1.00) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8981775 | 0.90 | RARA (0.82) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL4653891 | 0.90 | RARA (0.81) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8981526 | 0.89 | RARA (0.80) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL27463415 | 0.88 | RARA (0.78) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8981781 | 0.87 | RARA (0.77) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8771715 | 0.87 | RARA (0.77) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8771650 | 0.87 | RARB (0.77) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8981738 | 0.86 | RARA (0.76) | RARARARBRARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0661259-B1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL MYERS SQUIBB CO (US) | 1997-10-08 | — | — | EP | claimed |
| US-5618839-A | Retinoid-like compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-08 | — | — | US | claimed |
| CN-1144217-A | Retinoid-like compounds | BRISTOL MYERS SQUIBB CO (US) | 1997-03-05 | — | — | CN | claimed |
| EP-0661259-A1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-05 | — | — | EP | claimed |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210113507-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-20210113506-A1 | IMMUNOMODULATORY AND DIFFERENTIATING FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-10881628-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10874628-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10874627-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200147020-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | Io Therapeutics, Inc. | 2020-05-14 | — | — | US | disclosed |
| EP-1602354-B1 | Use of polyglutamic acid or its salts | MEIJI SEIKA KAISHA (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| EP-0661259-B1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL MYERS SQUIBB CO (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5648385-A | TREATING RHEUMATOID ARTHRITIS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5618839-A | Retinoid-like compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0661259-A1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210113507-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRG, RXRA, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-10881628-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRG, RXRA, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-20210113506-A1 | IMMUNOMODULATORY AND DIFFERENTIATING FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRA, RXRG, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-10874627-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRG, RXRA, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | RARA 1026/4885RARB 1581/4885RARG 733/4885 |
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | RARA 701/4885RARB 1212/4885RARG 842/4885 |
| US-20200147020-A1 | RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY | RXRG, RXRA, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
| US-10874628-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRG, RXRA, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.